Aclaris Therapeutics 2025 Q3 Earnings Beats Expectations Amid 92.6% Wider Net Loss

Aclaris Therapeutics (ACRS) reported fiscal 2025 Q3 earnings on Nov 6, 2025, with revenue and net loss figures diverging from expectations. The company exceeded revenue estimates despite a 24.1% year-over-year decline, . CEO Dr. Neal Walker emphasized progress in its pipeline, including Phase 2a trial success for ATI-2138 and a cash runway extending through mid-2028.

Revenue

Total revenue for Aclaris Therapeutics declined to $3.30 million in 2025 Q3, . The decrease was attributed to reduced milestones under prior licensing agreements, .

Earnings/Net Income

, . Earnings per share (EPS) fell to -$0.12, . The EPS result beat the $-0.13 consensus estimate, reflecting a narrower-than-expected loss despite sustained operational challenges.

Post-Earnings Price Action Review

Aclaris Therapeutics’ stock price declined 0.87% on the latest trading day and 8.84% over the past week, contrasting with a 23.37% monthly gain. The mixed performance highlights investor uncertainty amid the company’s prolonged losses and reliance on non-dilutive financing. Analysts remain cautiously optimistic, with seven “buy” ratings and no “sell” calls, .

CEO Commentary

Dr. Neal Walker highlighted advancements in Aclaris’ pipeline, , which demonstrated favorable tolerability and clinical improvements. He reiterated confidence in the company’s cash runway through 2028 and outlined plans to advance four clinical-stage candidates in 2026, including and biologics.

Guidance

Aclaris expects to initiate Phase 2 trials of ATI-2138 in additional indications (e.g., lichen planus) in H1 2026, . , .

Additional News

Recent non-earnings developments include:

1. Pipeline Advancements.

2. Zacks Rank Update: The stock was assigned a Zacks Rank #3 (Hold), .

3. Capital Strategy: Management emphasized opportunities for non-dilutive financing, including , .

Article Polishing

Transitions between sections have been refined for clarity, and punctuation inconsistencies resolved. All numerical data and structural elements remain unchanged. Placeholders (

,

) are embedded naturally within the article flow, adhering to formatting constraints.